The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer

I. Sinilkin, V. Chernov, A. Medvedeva, R. Zeltchan, E. Slonimskaya, A. Doroshenko, N. Varlamova, V. Skuridin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n = 34) were injected with radioactive 99mTc-Al2O3, and Group II patients (n = 30) received 99mTc-labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. 18 hours after 99mTc-Al2O3 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II SLNs were detected in 27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. The new radiopharmaceutical based on the 99mTc-Al2O3 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The sensitivity and specificity of 99mTc-Al2O3 were 100% for both SPECT and intraoperative gamma probe identification.

Original languageEnglish
Title of host publicationPhysics of Cancer
Subtitle of host publicationInterdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016
PublisherAmerican Institute of Physics Inc.
Volume1760
ISBN (Electronic)9780735414181
DOIs
Publication statusPublished - 2 Aug 2016
EventInternational Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016, PC 2016 - Tomsk, Russian Federation
Duration: 22 Mar 201625 Mar 2016

Conference

ConferenceInternational Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016, PC 2016
CountryRussian Federation
CityTomsk
Period22.3.1625.3.16

Fingerprint

lymphatic system
breast
cancer
tomography
injection
probes
photons
colloids
technetium
surgery
aluminum oxides

ASJC Scopus subject areas

  • Physics and Astronomy(all)

Cite this

Sinilkin, I., Chernov, V., Medvedeva, A., Zeltchan, R., Slonimskaya, E., Doroshenko, A., ... Skuridin, V. (2016). The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. In Physics of Cancer: Interdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016 (Vol. 1760). [020061] American Institute of Physics Inc.. https://doi.org/10.1063/1.4960280

The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. / Sinilkin, I.; Chernov, V.; Medvedeva, A.; Zeltchan, R.; Slonimskaya, E.; Doroshenko, A.; Varlamova, N.; Skuridin, V.

Physics of Cancer: Interdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016. Vol. 1760 American Institute of Physics Inc., 2016. 020061.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Sinilkin, I, Chernov, V, Medvedeva, A, Zeltchan, R, Slonimskaya, E, Doroshenko, A, Varlamova, N & Skuridin, V 2016, The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. in Physics of Cancer: Interdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016. vol. 1760, 020061, American Institute of Physics Inc., International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016, PC 2016, Tomsk, Russian Federation, 22.3.16. https://doi.org/10.1063/1.4960280
Sinilkin I, Chernov V, Medvedeva A, Zeltchan R, Slonimskaya E, Doroshenko A et al. The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. In Physics of Cancer: Interdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016. Vol. 1760. American Institute of Physics Inc. 2016. 020061 https://doi.org/10.1063/1.4960280
Sinilkin, I. ; Chernov, V. ; Medvedeva, A. ; Zeltchan, R. ; Slonimskaya, E. ; Doroshenko, A. ; Varlamova, N. ; Skuridin, V. / The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. Physics of Cancer: Interdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016. Vol. 1760 American Institute of Physics Inc., 2016.
@inproceedings{02aad5bb4f164287b0e820a70950f111,
title = "The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer",
abstract = "Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n = 34) were injected with radioactive 99mTc-Al2O3, and Group II patients (n = 30) received 99mTc-labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. 18 hours after 99mTc-Al2O3 injection, the percentage of its accumulation in the SLN was 7-11{\%} (of the counts in the injection site) by SPECT and 17-31{\%} by gamma probe detection. In Group II SLNs were detected in 27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5-2{\%} out of the counts in the injection site by SPECT and 4-7{\%} by gamma probe. The new radiopharmaceutical based on the 99mTc-Al2O3 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The sensitivity and specificity of 99mTc-Al2O3 were 100{\%} for both SPECT and intraoperative gamma probe identification.",
author = "I. Sinilkin and V. Chernov and A. Medvedeva and R. Zeltchan and E. Slonimskaya and A. Doroshenko and N. Varlamova and V. Skuridin",
year = "2016",
month = "8",
day = "2",
doi = "10.1063/1.4960280",
language = "English",
volume = "1760",
booktitle = "Physics of Cancer",
publisher = "American Institute of Physics Inc.",

}

TY - GEN

T1 - The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer

AU - Sinilkin, I.

AU - Chernov, V.

AU - Medvedeva, A.

AU - Zeltchan, R.

AU - Slonimskaya, E.

AU - Doroshenko, A.

AU - Varlamova, N.

AU - Skuridin, V.

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n = 34) were injected with radioactive 99mTc-Al2O3, and Group II patients (n = 30) received 99mTc-labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. 18 hours after 99mTc-Al2O3 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II SLNs were detected in 27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. The new radiopharmaceutical based on the 99mTc-Al2O3 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The sensitivity and specificity of 99mTc-Al2O3 were 100% for both SPECT and intraoperative gamma probe identification.

AB - Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n = 34) were injected with radioactive 99mTc-Al2O3, and Group II patients (n = 30) received 99mTc-labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. 18 hours after 99mTc-Al2O3 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II SLNs were detected in 27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. The new radiopharmaceutical based on the 99mTc-Al2O3 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The sensitivity and specificity of 99mTc-Al2O3 were 100% for both SPECT and intraoperative gamma probe identification.

UR - http://www.scopus.com/inward/record.url?scp=84984567367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984567367&partnerID=8YFLogxK

U2 - 10.1063/1.4960280

DO - 10.1063/1.4960280

M3 - Conference contribution

VL - 1760

BT - Physics of Cancer

PB - American Institute of Physics Inc.

ER -